Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Optimal Goals for Anemia and Transfusion Independence in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

The Importance of Treating Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

Other Notable Myelofibrosis Data From ASH 2024

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.

Data for Navtemadlin in Relapsed/Refractory Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses post hoc overall survival data for pacritinib in myelofibrosis.

The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses the relationship between thrombocytopenia and anemia on disease progression in myelofibrosis

Challenges With Low-Dose Ruxolitinib in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses challenges with low-dose ruxolitinib in myelofibrosis.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

January 24th 2025

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

Dr Hunter on the Development of Targeted Approaches Beyond JAK Inhibition in Myelofibrosis

January 16th 2025

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

January 10th 2025

Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.

Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS

January 9th 2025

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis

January 7th 2025

Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS

January 7th 2025

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

January 6th 2025

Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis

January 6th 2025

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

Treatment Trends: JAK Inhibitor Selection in Myelofibrosis

December 20th 2024

Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.

Dissecting the Current Treatment Landscape in MDS

December 18th 2024

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

OB756 Showcases Favorable Tolerability in JAK Inhibitor–Naive Myelofibrosis

December 16th 2024

An investigative JAK2 inhibitor demonstrated acceptable tolerability and early clinical activity in patients with JAK inhibitor–naive myelofibrosis.